Platelet GPIIb-IIIa blockers
Regardless of the event that stimulates the aggregation of platelets, the receptor αllbβ3-one of a family of adhesion receptors known as integrins–has a key role in the process. The past decade has seen the publication of 10 phase III (randomised) clinical trials of four members of a new class of an...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 1999-01, Vol.353 (9148), p.227-231 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 231 |
|---|---|
| container_issue | 9148 |
| container_start_page | 227 |
| container_title | The Lancet (British edition) |
| container_volume | 353 |
| creator | Topol, Eric J Byzova, Tatiana V Plow, Edward F |
| description | Regardless of the event that stimulates the aggregation of platelets, the receptor αllbβ3-one of a family of adhesion receptors known as integrins–has a key role in the process. The past decade has seen the publication of 10 phase III (randomised) clinical trials of four members of a new class of antiplatelet drugs, the GPIIb-IIIa blockers, targeted at this important receptor. Three (abciximab, eptifibatide, and tirofiban) are licensed for human use. 10 other GbIIb-IIIa blockers are in phase II or III human studies. In all 10 placebo-controlled trials, done in the clinical settings of percutaneous coronary intervention or acute coronary syndrome in patients on aspirin, the endpoints favoured the active drug, with a risk reduction for death or non-fatal myocardial infarction of about 21% overall. With attention to heparin dose the risk of bleeding is not a major concern with these agents. The GPIIb-IIIa blockers are taking the clinician and patient out of the era of aspirin monotherapy when platelet inhibition is required. |
| doi_str_mv | 10.1016/S0140-6736(98)11086-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69562799</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673698110863</els_id><sourcerecordid>69562799</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-a31b104fd9ef091e2f46617b83f8461490c9f493da7fba8dbd7fc1c6b9adb3783</originalsourceid><addsrcrecordid>eNqFkM1Kw0AYRQdRaq2-gYUiIrqIzmQm87MSKVoDBQsquBvmF1LTRGcSwbc3bUMFN66-xT338nEAGCN4jSCiN88QEZhQhuml4FcIQU4TvAeGiDCSZIS97YPhDjkERzEuIYSEwmwABkKkmAsyBKeLUjWudM1ktshzneR5ria6rM27C_EYHHhVRnfS3xF4fbh_mT4m86dZPr2bJ4Yg2iQKI40g8VY4DwVyqSeUIqY59pxQRAQ0whOBrWJeK261Zd4gQ7VQVmPG8QhcbHc_Qv3ZutjIVRGNK0tVubqNkoqMpkyIDjz7Ay7rNlTdbxIJLigjGe2gbAuZUMcYnJcfoVip8C0RlGt1cqNOrr1IweVGncRdb9yPt3rl7K7Vu-ry8z5X0ajSB1WZIv6OU8oZSzvsdou5zthX4YKMpnCVcbYIzjTS1sU_j_wAx8GHng</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>198967456</pqid></control><display><type>article</type><title>Platelet GPIIb-IIIa blockers</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Business Source Complete</source><source>ProQuest Central UK/Ireland</source><creator>Topol, Eric J ; Byzova, Tatiana V ; Plow, Edward F</creator><creatorcontrib>Topol, Eric J ; Byzova, Tatiana V ; Plow, Edward F</creatorcontrib><description>Regardless of the event that stimulates the aggregation of platelets, the receptor αllbβ3-one of a family of adhesion receptors known as integrins–has a key role in the process. The past decade has seen the publication of 10 phase III (randomised) clinical trials of four members of a new class of antiplatelet drugs, the GPIIb-IIIa blockers, targeted at this important receptor. Three (abciximab, eptifibatide, and tirofiban) are licensed for human use. 10 other GbIIb-IIIa blockers are in phase II or III human studies. In all 10 placebo-controlled trials, done in the clinical settings of percutaneous coronary intervention or acute coronary syndrome in patients on aspirin, the endpoints favoured the active drug, with a risk reduction for death or non-fatal myocardial infarction of about 21% overall. With attention to heparin dose the risk of bleeding is not a major concern with these agents. The GPIIb-IIIa blockers are taking the clinician and patient out of the era of aspirin monotherapy when platelet inhibition is required.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(98)11086-3</identifier><identifier>PMID: 9923894</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>Adhesion ; Biological and medical sciences ; Blood ; Blood. Blood coagulation. Reticuloendothelial system ; Clinical trials ; Humans ; Medical research ; Medical sciences ; Myocardial infarction ; Pharmaceuticals ; Pharmacology. Drug treatments ; Platelet Aggregation Inhibitors - chemistry ; Platelet Aggregation Inhibitors - therapeutic use ; Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors ; Risk reduction</subject><ispartof>The Lancet (British edition), 1999-01, Vol.353 (9148), p.227-231</ispartof><rights>1999 Elsevier Ltd</rights><rights>1999 INIST-CNRS</rights><rights>Copyright Lancet Ltd. Jan 16, 1999</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-a31b104fd9ef091e2f46617b83f8461490c9f493da7fba8dbd7fc1c6b9adb3783</citedby><cites>FETCH-LOGICAL-c416t-a31b104fd9ef091e2f46617b83f8461490c9f493da7fba8dbd7fc1c6b9adb3783</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/198967456?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976,64364,64366,64368,72218</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1668772$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9923894$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Topol, Eric J</creatorcontrib><creatorcontrib>Byzova, Tatiana V</creatorcontrib><creatorcontrib>Plow, Edward F</creatorcontrib><title>Platelet GPIIb-IIIa blockers</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>Regardless of the event that stimulates the aggregation of platelets, the receptor αllbβ3-one of a family of adhesion receptors known as integrins–has a key role in the process. The past decade has seen the publication of 10 phase III (randomised) clinical trials of four members of a new class of antiplatelet drugs, the GPIIb-IIIa blockers, targeted at this important receptor. Three (abciximab, eptifibatide, and tirofiban) are licensed for human use. 10 other GbIIb-IIIa blockers are in phase II or III human studies. In all 10 placebo-controlled trials, done in the clinical settings of percutaneous coronary intervention or acute coronary syndrome in patients on aspirin, the endpoints favoured the active drug, with a risk reduction for death or non-fatal myocardial infarction of about 21% overall. With attention to heparin dose the risk of bleeding is not a major concern with these agents. The GPIIb-IIIa blockers are taking the clinician and patient out of the era of aspirin monotherapy when platelet inhibition is required.</description><subject>Adhesion</subject><subject>Biological and medical sciences</subject><subject>Blood</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Clinical trials</subject><subject>Humans</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Myocardial infarction</subject><subject>Pharmaceuticals</subject><subject>Pharmacology. Drug treatments</subject><subject>Platelet Aggregation Inhibitors - chemistry</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors</subject><subject>Risk reduction</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkM1Kw0AYRQdRaq2-gYUiIrqIzmQm87MSKVoDBQsquBvmF1LTRGcSwbc3bUMFN66-xT338nEAGCN4jSCiN88QEZhQhuml4FcIQU4TvAeGiDCSZIS97YPhDjkERzEuIYSEwmwABkKkmAsyBKeLUjWudM1ktshzneR5ria6rM27C_EYHHhVRnfS3xF4fbh_mT4m86dZPr2bJ4Yg2iQKI40g8VY4DwVyqSeUIqY59pxQRAQ0whOBrWJeK261Zd4gQ7VQVmPG8QhcbHc_Qv3ZutjIVRGNK0tVubqNkoqMpkyIDjz7Ay7rNlTdbxIJLigjGe2gbAuZUMcYnJcfoVip8C0RlGt1cqNOrr1IweVGncRdb9yPt3rl7K7Vu-ry8z5X0ajSB1WZIv6OU8oZSzvsdou5zthX4YKMpnCVcbYIzjTS1sU_j_wAx8GHng</recordid><startdate>19990116</startdate><enddate>19990116</enddate><creator>Topol, Eric J</creator><creator>Byzova, Tatiana V</creator><creator>Plow, Edward F</creator><general>Elsevier Ltd</general><general>Lancet</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>19990116</creationdate><title>Platelet GPIIb-IIIa blockers</title><author>Topol, Eric J ; Byzova, Tatiana V ; Plow, Edward F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-a31b104fd9ef091e2f46617b83f8461490c9f493da7fba8dbd7fc1c6b9adb3783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adhesion</topic><topic>Biological and medical sciences</topic><topic>Blood</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Clinical trials</topic><topic>Humans</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Myocardial infarction</topic><topic>Pharmaceuticals</topic><topic>Pharmacology. Drug treatments</topic><topic>Platelet Aggregation Inhibitors - chemistry</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors</topic><topic>Risk reduction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Topol, Eric J</creatorcontrib><creatorcontrib>Byzova, Tatiana V</creatorcontrib><creatorcontrib>Plow, Edward F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News & ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Topol, Eric J</au><au>Byzova, Tatiana V</au><au>Plow, Edward F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Platelet GPIIb-IIIa blockers</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>1999-01-16</date><risdate>1999</risdate><volume>353</volume><issue>9148</issue><spage>227</spage><epage>231</epage><pages>227-231</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><coden>LANCAO</coden><abstract>Regardless of the event that stimulates the aggregation of platelets, the receptor αllbβ3-one of a family of adhesion receptors known as integrins–has a key role in the process. The past decade has seen the publication of 10 phase III (randomised) clinical trials of four members of a new class of antiplatelet drugs, the GPIIb-IIIa blockers, targeted at this important receptor. Three (abciximab, eptifibatide, and tirofiban) are licensed for human use. 10 other GbIIb-IIIa blockers are in phase II or III human studies. In all 10 placebo-controlled trials, done in the clinical settings of percutaneous coronary intervention or acute coronary syndrome in patients on aspirin, the endpoints favoured the active drug, with a risk reduction for death or non-fatal myocardial infarction of about 21% overall. With attention to heparin dose the risk of bleeding is not a major concern with these agents. The GPIIb-IIIa blockers are taking the clinician and patient out of the era of aspirin monotherapy when platelet inhibition is required.</abstract><cop>London</cop><pub>Elsevier Ltd</pub><pmid>9923894</pmid><doi>10.1016/S0140-6736(98)11086-3</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 1999-01, Vol.353 (9148), p.227-231 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69562799 |
| source | MEDLINE; Elsevier ScienceDirect Journals; Business Source Complete; ProQuest Central UK/Ireland |
| subjects | Adhesion Biological and medical sciences Blood Blood. Blood coagulation. Reticuloendothelial system Clinical trials Humans Medical research Medical sciences Myocardial infarction Pharmaceuticals Pharmacology. Drug treatments Platelet Aggregation Inhibitors - chemistry Platelet Aggregation Inhibitors - therapeutic use Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors Risk reduction |
| title | Platelet GPIIb-IIIa blockers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T03%3A56%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Platelet%20GPIIb-IIIa%20blockers&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Topol,%20Eric%20J&rft.date=1999-01-16&rft.volume=353&rft.issue=9148&rft.spage=227&rft.epage=231&rft.pages=227-231&rft.issn=0140-6736&rft.eissn=1474-547X&rft.coden=LANCAO&rft_id=info:doi/10.1016/S0140-6736(98)11086-3&rft_dat=%3Cproquest_cross%3E69562799%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=198967456&rft_id=info:pmid/9923894&rft_els_id=S0140673698110863&rfr_iscdi=true |